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Summary Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated
with high dose (140-260mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide
"(priming" 300mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not
histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of
tumour response to treatment and in 2 patients complete remissions were observed. However in most patients,
responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months
from first recorded evidence ofdistant metastatic disease.
Treatment results for metastatic malignant
melanoma remain extremely disappointing. The
best single agents produce objective response rates
of only 20-25% (Bellet et al., 1979, Retsas et al.,
1980) and combinations ofcytotoxic drugs have not
given improved response rates [Bellet et al., 1979].
Furthermore it is doubtful whether many of these
responses result in significant prolongation of life
since most responses are seen in skin and regional
node metastases, while metastases in life-threatening
visceral sites seldom respond and complete
remissions are extremely rare. There is, therefore,
an urgent need to devise new approaches to the
treatment of this tumour. One such approach is to
use very high dose chemotherapy and preliminary
work in this direction has been done by us
(McElwain et al., 1979) with melphalan and by
Thomas et al. (1982) using nitrogen mustard,
BCNU and melphalan.
Our decision to evaluate high dose melphalan in
advanced life-threatening disease has stemmed from
both clinical and experimental observations.
Although conventional doses of melphalan (10mg
p.o. per day for 5 days each month) produce a
response rate of only 9% (Luce, 1975), the much
higher concentrations produced when the drug is
used in closed-limb perfusions are more effective
and give a useful means of achieving local control
(Rosin & Westbury, 1980). Studies using human
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malignant melanomas grown as xenografts in
neonatally-thymectomised mice show a log-linear
dose-response to melphalan doses in the range 5-
25mgkg-1 (Selby et al., 1980). Attempts to achieve
comparably high systemic concentrations of
melphalan in man are hindered by the inevitability
of profound haematological toxicity and the
probability of encountering a dose-limiting second
organ toxicity. We had already established that the
bone marrow toxicity of melphalan at a dose of
140mgm-2 could be reduced to a clinically
acceptable level by either autologous bone marrow
rescue (McElwain et al., 1979) or by pre-treatment
with cyclophosphamide ("priming") (Hedley et al.,
1978). The objectives of the present study were first,
to assess the therapeutic value of an aggressive
treatment approach in advanced malignant
melqnoma; second, to investigate whether a dose
response effect could be seen in man; third, to
establish the maximum dose of melphalan that may
safely be given to patients and fourth to investigate
whether "priming" with cyclophosphamide exerted
a protective effect on the melphalan-treated gut, as
had been shown by us in mice and sheep (Millar et
al., 1978ab).
We report here the results of treating 28 patients
with life-threatening visceral metastatic melanoma
with doses of melphalan ranging from 140-
260mgm-2, all of whom received autologous bone
marrow rescue and 19 of whom were pre-treated
with cyclophosphamide.
Patients and methods
Patients with histologically proven malignant
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melanoma and life-threatening visceral metastases
were considered for inclusion if they were aged
<60 years, did not have brain or bone marrow
involvement, had an anticipated life expectancy of
<3 months and had no other medical
contraindication. Twenty-eight such patients were
treated and their characteristics and the distribution
of tumour involved sites are shown in Table I.
Although 60% of patients had skin and/or node
involvement, such metastases on their own were not
a sufficient criterion for inclusion of the patients in
this study. Ten patients had received prior
chemotherapy, 5 with DTIC and vincristine, and 5
with vindesine, but none had received any
chemotherapy in the month prior to treatment with
melphalan.
Table I Patient characteristics
Mean age 38
Male Female
Primary site
Head & neck
Trunk
Leg
Arm
Metastatic site
Skin
Lung
Liver
Abdominal or
pelvic mass
Regional
lymph node(s)
Bone
(range 19-58)
14/14
6 (ocular 3)
9
9
4
15 (54%)
13 (46%)
12 (43%)
6 (21%)
6 (21%)
5 (18%)
Pre-treatment investigations included full blood
count, urea and electrolytes, liver function tests,
bone marrow aspirate and trephine, liver and bone
isotope scans and chest x-rays.
The starting dose of melphalan was 140mgm 2
This was increased by 15 mgm2 as shown in Table
II, non cyclophosphamide-primed patients being
studied before primed patients at each melphalan
dose level. At most dose levels there were 2 primed
and 2 unprimed patients. The priming dose of
cyclophosphamide (300mg m 2 i.v.) was given 7
days before treatment with melphalan in all cases.
This time interval had been found to enhance bone
Marrow recovery in man (Hedley et al., 1978) and
was similar to the time interval associated with
amelioration of gut toxicity in the sheep (Miller et
al., 1978b). On the day of treatment, a central
venous line was introduced and the patient
catheterised. A general anaesthetic was given, the
patient was heparinised and
- 2 x 108 nucleated
bone marrow cells kg-1 body wt were aspirated
from both anterior and posterior iliac crests and the
Table II Twenty-eight patients: Treatment details
No. ofpatients
Dose ofmelphalan mgm2 Primed Not primed
140 2 2
155 2 2
170 2 3
185 2 2
200 2
215 2
230 3
245 2
260 2
sternum. The marrow was heparinised and stored
at 4°C as previously reported (McElwain et al.,
1979). After the start of a forced diuresis, a bolus
injection of melphalan was given via the central
venous line and i.v. fluids were then given to ensure
a urine output of >200mlh- for the following 8h.
Anti-emetics were given regularly and pulse, blood
pressure and central venous pressure closely
monitored. The bone marrow was reinfused via a
peripheral vein 8-14h after the melphalan injection.
A conventional blood giving set with no additional
filtration was used.
Patients underwent jejunal biopsy with a Crosby
capsule 5 days after melphalan administration,
immediately before the onset of thrombocytopenia.
The tissues were fixed in 10% formal saline,
processed routinely and stained with haematoxylin
and eosin.
Responses were classified as either complete
(CR), partial (PR) or no response (NR). Complete
remission was defined as the complete resolution of
all demonstrable disease maintained for a minimum
of 30 days. Partial remission was defined as a
>50% reduction in the products of diameters of all
measurable lesions maintained for 30 days during
which no new lesions appeared. Patients who
achieved a partial remission after one treatment
were considered for a second treatment after a
period of convalescence of at least 6 weeks. Seven
patients received a second course of treatment, in
every case with 140mgm 2 ofmelphalan.
Results
Toxicity
As anticipated, the main toxicity was
haematological (Table III). Neutropenia (neutrophil
count <.1000x 091-1) predictably developed
between days 5 and 7 following treatment andHIGH DOSE MELPHALAN FOR MALIGNANT MELANOMA 331
Table III Toxicity of high-dose melphalan
Neutropenia 28 (100%)
Thrombocytopenia 28 (100%)
Alopecia 28 (100%)
Nausea & vomiting 28 (100%)
Diarrhoea 12 (43%)
moderate 8
severe 4
Stomatitis 12 (43%)
Depression 5 (18%)
Elevated blood urea 4 (14%)
Early hypotension 2 (7%)
lasted for a mean period of 9.4 days (range 2-16
days). Thrombocytopenia (platelet count
< 50,000 x 1091-1) developed slightly later and
lasted longer-mean 11.3 days (range 5-22 days).
There was no difference in the duration of
cytopenia between those (17) receiving doses of
< 185mmm 2 and those (11) receiving
>200mgm-2 melphalan (Figure 1). However,
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Figure 1 Mean leucocyte, neutrophil and platelet
counts (x1091-l) in 17 patients receiving melphalan
doses of 0185MgM2 and 11 patients receiving
.200mgm2. Vertical bars show +1 s.d. about the
mean.
haematological recovery was considerably slower in
the 7 patients who received a second treatment with
a similar dose of melphalan (Figure 2). All patients
received prophylactic cotrimoxazole prior to the
onset of neutropenia, and i.v. antibiotics and
platelet transfusions were given as indicated. White
cell transfusions were not required.
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Figure 2 Mean leucocyte, neutrophil and platelet
counts (x1091-) in 28 patients after receiving first
course of melphalan compared with the recovery
pattern in 7 of these patients who received a second
course. Vertical bars show +1 s.d. about the mean.
The major manifestations of gastrointestinal
toxicity attributable to melphalan were stomatitis
and diarrhoea. Significant stomatitis occurred in
43% of patients. In those patients pre-treated with
cyclophosphamide, the dose of melphalan was
increased to 260mgm-2 before clinically
unacceptable gut toxicity was manifest in the form
of severe stomatitis with profuse, watery diarrhoea
(>6 motions per day). Severe stomatitis was held
to have occurred if the patient had a sore mouth
with deep mucosal ulceration and could not take
solid food but could continue to drink with
discomfort. This was managed with fluid and
electrolyte replacement and resolved at the time of332 M.A. CORNBLEET et al.
recovery of the neutrophil count. Similar severe
stomatitis and diarrhoea were encountered in
unprimed patients when the dose escalation reached
185mgm2. Diarrhoea of this severity was
regarded as dose-limiting and it was concluded that
245 mg m 2 in primed patients and 170 mgm-2 in
unprimed patients were the maximum tolerated
doses. The jejunal biopsies showed varying degrees
of villous atrophy together with focal ulceration
and dysplasia in the mucosa lining villi and crypts.
No consistent differences were detected between
biopsies from primed and unprimed patients, and
the extent of tissue damage sustained by the crypts
and villi did not correlate with the subsequent
development of diarrhoea. It is possible that
histological differences might be present at Day 8,
the time of severe diarrhoea, but since all the
patients were thrombocytopenic at this time small
bowel biopsy could not be justified and it was thus
not possible to confirm histologically the protective
effect on the human gut of priming with
cyclophosphamide which was apparent clinically.
Five patients became markedly depressed during
the second week following melphalan. Anti-
depressant therapy was of little benefit,
improvement usually accompanying recovery from
physical side effects.
Transient elevations in blood urea concentration
were observed in 4 patients but were of no clinical
significance. In 2 patients, this elevation followed a
brief period of hypotension during the immediate
post-anaesthetic phase early in the study.
Subsequently, all patients were transfused with 1-2
units of whole blood during the marrow aspiration
and hypotension was not seen again.
Five patients died within one month of receiving
melphalan. At autopsy one was found to have a
perforation of the ileum at the site of a melanoma
deposit. The other early deaths were from
progressive tumour.
Anti-tumour effect
Twelve patients (43%) achieved a partial remission
after one course of treatment, and 7 subsequently
underwent a second treatment. Of these, 5 were
retreated at the same dose and 2 at a reduced dose,
both receiving 140mgm 2 on that occasion having
received 230mgm-2 first. Two of these patients
went on to achieve a complete remission. The
response rates at different metastatic sites are
shown in Table IV. Although no objective
responses were recorded in bone metastases, all 5
patients experienced a rapid and lasting
improvement in previously severe bone pain, and 4
were able to discontinue regular analgesic usage for
the rest of their lives.
Table IV Response rate by site ofmetastases
Involved Response
Abdominal or pelvic
lymph node mass 6 4 (67)
Peripheral lymph
node 6 1 (16)
Skin 15 9 (60)
Liver 12 6 (50)
Lung 13 6 (46)
Bone 5 0 (0)
Partial or complete responses were observed in
7/11 patients receiving .200mgm-2 melphalan,
compared with 5 of 17 patients receiving
<185mgm .2 Median duration of survival was 9
months from time of treatment in the higher dose
group compared with 4 months in the lower dose
group (Figure 3). However, when survival is
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Figure 3 Survival of 17 patients receiving melphalan
doses of <185mgm-2 compared with that of 11
patients receiving .200mg 2 measured from time of
first treatment with melphalan.
measured from the time of tumour dissemination
instead of from the time of treatment, the difference
between the groups is reduced and the two survival
curves cross (Figure 4). All the patients in the
higher dose group had been pre-treated with
cyclophosphamide and the lack of any suggestion
that they fared worse than unprimed patients lends
support to the experimental observation that the
normal tissue-sparing effects of pre-treatment with
cyclophosphamide do not result in protection of
clonogenic tumour stem cells (Miller et al., 1978a).
Median survival of complete and partial
responders was 9 months compared with 4 months
for non-responders, if survival is measured from the
time of treatment (Figure 5). A better indicator of
the impact of any treatment on the natural history
of the disease is to measure survival from a fixed
point in that natural history rather than from theHIGH DOSE MELPHALAN FOR MALIGNANT MELANOMA 333
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Figure 6 Survival of same patients as
Survival measured from time of first recc
of distant metastases.
arbitrary (and variable) point at which the decision
to treat is taken. When analysed in this way, from
the time of first recorded evidence of distant
metastasis, no real difference in survival between
responders and non-responders is seen (Figure 6).
Discussion
The role of high dose melphalan with autologous
marrow rescue in the management of advanced
malignant melanoma has been evaluated both in
20 24 terms of its feasibility and its effectiveness. Single
doses of up to 245mgm 2 can be given in patients
snFigure 3 pre-treated with cyclophosphamide before the
lein f 3t gastrointestinal toxicity becomes dose-limiting; in
patients not primed with cyclophosphamide, the
maximum tolerable dose is 170mgm2. It is clear
why autologous marrow rescue is of benefit to the
patient under these circumstances but less clear why
cyclophosphamide priming reduced the clinical
features of gastrointestinal toxicity. Previous work
by us in sheep (Miller et al., 1978b) showed
histologically that priming reduced the damage to
the intestinal mucosa by high dose melphalan, and
it was hoped that samples taken from patients by
Crosby capsule would yield similar results.
However those samples taken on Day 5 post-
melphalan did not demonstrate histologically the
benefit of priming in man seen clinically. We think
14 16 that a biopsy at Day 8 would have been more
appropriate since this would have coincided with
the onset of diarrhoea and probably the point of
nhose tumour maximum expression of gut damage. Unfortunately
no (CR+PR) thisalsocoincidedwiththeonsetofthrombocytopenia
nour did not and we felt that it was unethical to expose
rom time of thrombocytopenic patients to the risks of a gut
4o response. biopsy. We feel that we still only have "soft"
evidence that cyclophosphamide priming
ameliorates gut toxicity in man and that further
studies, probably where gut function is considered,
will need to be done before we can be certain of
benefit from the priming procedure.
The rate of recovery of neutrophils and platelets
was not related to the dose of melphalan used on
the first occasion which suggests that the initial
blood count recovery was due to repopulation of
the bone marrow by the graft.
Recovery of neutrophils and platelets in patients
rescued with their own marrow a second time (i.e.
after the second course of therapy) was slower on
the second occasion. This suggests that the bone
marrow stem cells in the marrow not removed for
20 24 transfusion (the major proportion) are greatly
depleted by the first treatment and that the
5 in Figure 5. transfused, untreated marrow taken from one or
)rded evidence two fairly restricted sites is diluted by dispersing
and repopulating the sites of haemopoiesis. On334 M.A. CORNBLEET et al.
reharvesting, the marrow stem cells would have
come predominantly from stem cells in the original
transfusion rather than from recovery of
endogenous treated marrow. Animal studies by
Siminovitch and others (Siminovitch et al., 1964,
Botnick et al., 1979, Rosendaal et al., 1979) have
demonstrated that the repopulating capacity of the
marrow stem cells is large but not infinite.
Therefore, in man, we think that the slower second
repopulation reflects this decrease in the marrow
reserve. This problem could probably be overcome
by cryopreservation of some of the bone marrow at
the time of the first transplant. However, in the
case of melanoma such a procedure is hardly
justified in view of the relatively poor anti-tumour
effect of this therapy. Should this method of
treatment be used in more sensitive tumours, such
as embryomal neoplasms of children, consideration
needs to be given to bone marrow storage.
Since it is possible to identify poor prognostic
factors in malignant melanoma with considerable
precision, much effort has been expended in the
search for an effective adjuvant treatment and such
was our purpose here, since even a treatment with
considerable toxicity might have a role as an
adjuvant if a high rate of complete remission had
been observed. Although a response rate of 43% in
advanced disease is better than can be achieved
with other single agents the relative lack of
complete remissions would not lead us to use this
treatment as an adjuvant. However a higher
remission rate might have been observed in a group
of patients with small numbers of small metastases
and if this were so a trial of adjuvant melphalan
could be contemplated. We are now looking at this
question in selected patients.
Although gloomy in themselves, these results do
illustrate some of the difficulties encountered in
interpreting the chemotherapy literature of this
disease. Neither high-dose vs low-dose patients, nor
responders vs non-responders could be shown to
have an improved survival from time of recorded
evidence of dissemination. This suggests that such
responses as were seen conferred little or no
survival benefit and the fact that responding
patients live a little longer than non responders if
their survival is measured from onset of treatment
probably means that they were treated earlier in the
natural history of their disease. The impact of the
treatment on the natural history of the disease, the
major test of usefulness of any new treatment, is
therefore small at best, although responses may, of
course, confer some other palliative benefit, such as
pain relief, while not lengthening life. Studies in
which small numbers of patients with differing
metastatic patterns (i.e. patients with regional node
disease only and those with widespread soft-tissue
or life-threatening visceral metastases) are combined
cannot address this problem and tend to produce
over-optimistic reports of "response rates" which
may not translate into actual patient survival
benefit.
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